With newly proposed legislation, the courts split and statutory authority at issue, this is the ideal time for stakeholders to convene, communicate, and explore "what's next" in compounding oversight. Join FDLI for our upcoming program -- Pharmacy Compounding: An FDLI Dialogue-- on Feb. 12 in Washington, D.C. During the first panel, Regulation of Pharmacy Compounding: Historical Analysis, panelists will lead an interactive discussion on the historical framework of the regulation of pharmacy compounding. Panelists include:
- Douglas B. Farquhar, director, Hymann, Phelps & McNamara P.C.
- Casey Kozlowski, R.Ph., M.B.A., director, retail ancillary services, Walgreen Co.
- William A. McConagha, partner, Sidley Austin LLP
Published in Brief: